The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 1, 2002, Pages 45-49

  Margolis, David M ^a   Kewn, Stephen ^a   Coull, Jason J ^a   Ylisastigui, Loyda ^a   Turner, Diana ^a   Wise, Holly ^a   Hossain, Mohammed M ^a   Lanier, E Randall ^a   Shaw, Leslie M ^a   Back, David ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Mycophenolate; Nucleoside; Resistance; Salvage

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CARBOVIR; DEOXYGUANOSINE TRIPHOSPHATE; DIDANOSINE; DRUG METABOLITE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOCYTE COUNT; PRIORITY JOURNAL; SIDE EFFECT; URINARY TRACT INFECTION; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0036738830     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200209010-00006     Document Type: Article

References (16)

1. Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994;46:767-72.
2. Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211:554-60.
3. Margolis D, Heredia A, Gaywee J, et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999;21:362-70.
4. Chapuis AG, Rizzardi G, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000;6:762-8.
5. Allison AC, Kowalski WJ, Muller CD, et al. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993;696:63-87.
6. Faletto MB, Miller WH, Garvey EP, et al. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997;41:1099-1107.
7. Heredia A, Margolis D, Oldach D, et al. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH) inhibitor mycophenolic acid is active against multidrug-resistant HIV-1 [letter] [published erratum appears in J Acquir Immune Defic Syndr 2000;23:105]. J Acquir Immune Defic Syndr 1999,22:406-07.
8. Coull JJ, Turner D, Betts M, et al. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 2001:26:423-34.
9. Kewn S, Hoggard PG, Sales SD, et al. The development of enzymatic assays for the quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from HIV-infected patients. Antimicrob Agents Chemother 2002;46:135-43.
10. Shaw LM, Korecka M, van Breemen R, et al. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem 1998;31:323-28.
11. Hale MD, Nicholls AJ, Bullingham R. The pharmacokinetic pharmaeodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-83.
12. Ju ST, Matsui K, Ozdemirli M. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction. Int Rev Immunol 1999;18:485-513.
13. Peter ME, Ehret A, Berndt C, et al. AIDS and the death receptors. Br Med Bull 1997;53:604-16.
14. + T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses 1999;15:1509-18.
15. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a round-table discussion. Ther Drug Monit 2001;23:305-15.
16. Hossain MM, Margolis DM. Inhibition of HIV replication by mycophenolic acid with combinations of nucleoside and nucleotide reverse transcriptase inhibitors. Antiviral Res 2002;55:41-52.